Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies.
Nuccio A, Viscardi G, Salomone F, Servetto A, Venanzi FM, Riva ST, Oresti S, Ogliari FR, Viganò M, Bulotta A, Cameron R, Esposito A, Hines J, Bianco R, Reni M, Cascone T, Garassino MC, Torri V, Veronesi G, Cinquini M, Ferrara R. Nuccio A, et al. Among authors: servetto a. Eur J Cancer. 2023 Dec;195:113404. doi: 10.1016/j.ejca.2023.113404. Epub 2023 Oct 26. Eur J Cancer. 2023. PMID: 37948842
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review.
Servetto A, Salomone F, Di Costanzo F, Iuliano R, Marandino L, Napolitano F, Santaniello A, De Placido P, De Placido S, Di Maio M, Formisano L, Bianco R. Servetto A, et al. Crit Rev Oncol Hematol. 2022 Apr;172:103649. doi: 10.1016/j.critrevonc.2022.103649. Epub 2022 Mar 5. Crit Rev Oncol Hematol. 2022. PMID: 35259486 Review.
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review.
Viscardi G, Vitiello F, Servetto A, Gristina V, Pizzutilo EG, Canciello MA, Medusa PM, Salomone F, Di Guida G, Mollica M, Aronne L, Scaramuzzi R, Napolitano F, Battiloro C, Caputo F, Gilli M, Totaro G, Curcio C, Rocco D, Montesarchio V. Viscardi G, et al. Among authors: servetto a. Cancers (Basel). 2022 Nov 25;14(23):5810. doi: 10.3390/cancers14235810. Cancers (Basel). 2022. PMID: 36497292 Free PMC article. Review.
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions.
De Falco V, Suarato G, Napolitano R, Argenziano G, Famiglietti V, Amato A, Servetto A, Bianco R, Formisano L, Terrano V, Esposito A, Giugliano MC, Ciardiello D, Ciardiello F, Napolitano S, Troiani T. De Falco V, et al. Among authors: servetto a. Int J Cancer. 2023 Jul 1;153(1):133-140. doi: 10.1002/ijc.34462. Epub 2023 Feb 21. Int J Cancer. 2023. PMID: 36752579
42 results